Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Cholangiocarcinoma
Cholangiocarcinoma
Recent Developments in Genomic-Driven Therapies for Cholangiocarcinoma
Cholangiocarcinoma
,
Personalized Medicine
Web Exclusives
Personalized medicine has expanded the treatment options for patients with cholangiocarcinoma (CCA). At the 2021 Annual Meeting of the Cholangiocarcinoma Foundation (CCF), Ghassan K. Abou-Alfa, MD, MBA, Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, discussed recent developments in personalized therapies, highlighting genomic alterations that are informing the new therapies for patients with CCA.
Read Article
Truseltiq Receives FDA Approval for the Treatment of Patients with Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
Cholangiocarcinoma
,
FDA Approvals, News & Updates
August 2021, Vol 12, No 4
On
May 28, 2021
, the FDA accelerated the approval of infigratinib (Truseltiq; QED Therapeutics), an oral kinase inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) and
FGFR2
fusion or other rearrangement, as detected by an FDA-approved test. The FDA granted infigratinib priority and fast-track review, as well as orphan drug designation for this indication.
Read Article
Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
By
Loretta Fala
Cholangiocarcinoma
,
Drug Updates
August 2021, Vol 12, No 4
Cholangiocarcinoma (CCA) represents a group of heterogeneous cancers that originate in the bile ducts that connect the liver and gallbladder to the small intestine. Although the exact prevalence of CCA is unknown, CCA is a rare cancer; approximately 8000 new cases of CCA are diagnosed annually in the United States.
Read Article
Incorporating FGFR Inhibitors into the Treatment Paradigm for Cholangiocarcinoma: Current Concepts and Future Directions
By
Mitesh Borad, MD
;
Milind M. Javle, MD
;
Michael Morse, MD, FACP, MHS
;
Lewis R. Roberts, MB, ChB, PhD
Cholangiocarcinoma
,
Continuing Education
June 2021, Vol 12, No 3
On January 15, 2021, experts in the management of patients with cholangiocarcinoma (CCA) convened for a virtual accredited continuing education satellite symposium held during the 2021 annual meeting of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The goal was to educate healthcare providers on various aspects of CCA, including epidemiology, current standards of care, unmet clinical needs, the safety and efficacy of fibroblast growth factor receptor (
FGFR
) inhibitors as second-line therapy, and practical approaches to incorporating
FGFR
inhibitors into the treatment paradigm for the disease.
Read Article
Final Results from ClarIDHy: Ivosidenib Extends Survival in Patients with Cholangiocarcinoma and IDH1 Mutation
By
Wayne Kuznar
ASCO 2021 Highlights
,
Cholangiocarcinoma
April 2021, Vol 12, No 2
Final results from the phase 3 clinical trial ClarIDHy showed that ivosidenib (Tibsovo), a first-in-class oral inhibitor of isocitrate dehydrogenase 1 (
IDH1
) mutation, prolonged the median overall survival (OS) in patients with previously treated advanced cholangiocarcinoma (CCA) and
IDH1
mutation. Although this improvement did not reach statistical significance, after adjusting for crossovers from the placebo to the ivosidenib group, the difference in median OS was statistically significant.
Read Article
Targeted Therapies in Cholangiocarcinoma
Cholangiocarcinoma
February 2021, Vol 12, No 1
The recent FDA approval of the first
FGFR
inhibitor, pemigatinib (Pemazyre), and the positive results from the phase 3 study of the first
IDH1
inhibitor, ivosidenib (Tibsovo), represent major breakthroughs in the treatment of patients with cholangiocarcinoma (CCA), a rare cancer associated with poor outcomes. However, the duration of response with these agents is still relatively short.
Read Article
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
Cholangiocarcinoma
February 2021, Vol 12, No 1
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).
Read Article
Managing Cholangiocarcinoma in the Setting of COVID-19: Unique Challenges and Opportunities
By
Ghassan K. Abou-Alfa, MD, MBA
;
Bruce Lin, MD
;
Farshid Dayyani, MD, PhD
;
Richard Kim, MD
;
Rachna T. Shroff, MD, MS
;
Melinda Bachini
;
Milind M. Javle, MD
Cholangiocarcinoma
,
COVID-19
December 2020, Special Issue: Managing CCA in the Setting of COVID-19
The first confirmed case in the United States of the 2019 novel coronavirus (COVID-19) was reported on January 21, 2020, and as of November 27, 2020, there were >63 million confirmed cases and >1.5 million deaths globally. Despite the global impact, certain populations have been identified as having a higher risk of developing severe COVID-19 infection, including patients with cancer. Various studies have shown that patients with cancer experience particularly poor outcomes after COVID-19 infection. As a result of the pandemic, care delivery has been disrupted to some degree based on the need for prioritization and limitations on resources. Therefore, healthcare providers and patients have been continually reassessing the balance between the benefits and risks of anticancer interventions in the context of the added risk of COVID-19 infection.
Read Article
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
By
Chase Doyle
Cholangiocarcinoma
December 2020, Vol 11, No 6
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in applying the use of targeted therapies in the treatment of patients with cholangiocarcinoma (CCA).
Read Article
FGFR Inhibition in Cholangiocarcinoma and Resistance to Therapy
By
Chase Doyle
Cholangiocarcinoma
December 2020, Vol 11, No 6
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The
FGFR
inhibitor was approved for adults with CCA and
FGFR2
fusion.
Read Article
Page 2 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma